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Evidence that activating mutations of the KRAS onco-
gene abolish the response to anti-epidermal growth
factor receptor therapy has revolutionized the treat-
ment of advanced colorectal cancer. This has resulted
in the urgent demand for KRAS mutation testing in
the clinical setting to aid choice of therapy. The aim of
this study was to evaluate six different KRAS mutation
detection methodologies on two series of primary colo-
rectal cancer samples. Two series of 80 frozen and 74
formalin-fixed paraffin-embedded tissue samples were
sourced and DNA was extracted at a central site before
distribution to seven different testing sites. KRAS muta-
tions in codons 12 and 13 were assessed by using single
strand conformation polymorphism analysis, pyrose-
quencing, high resolution melting analysis, dideoxy se-
quencing, or the commercially available TIB Molbiol
(Berlin, Germany) or DxS Diagnostic Innovations
(Manchester, UK) kits. In frozen tissue samples, concor-
dance in KRAS status (defined as consensus in at least
five assays) was observed in 66/80 (83%) cases. In par-
affin tissue, concordance was 46/74 (63%) if all assays
were considered or 71/74 (96%) using the five best per-
forming assays. These results demonstrate that a va-
riety of detection methodologies are suitable and
provide comparable results for KRAS mutation anal-
ysis of clinical samples. (J Mol Diagn 2009, 11:543–552;
DOI: 10.2353/jmoldx.2009.090057)
The epidermal growth factor receptor (EGFR) mediates
molecular events critical to cellular growth and survival.
This receptor is up-regulated in the majority of colorectal
cancers (CRCs) and contributes to cancer progression
by modulation of events such as proliferation, adhesion,
and angiogenesis.1,2 EGFR therefore presents an excel-
lent candidate for targeted therapy.3 Monoclonal anti-
body treatments such as cetuximab have been devel-
oped that target the extracellular binding domain of
EGFR, thus competitively inhibiting the binding of ligand
to its receptor. However, a significant proportion of EGFR
positive CRCs remain resistant to this therapy. One rea-
son for resistance is that the pathway may also be acti-
vated downstream of EGFR due to mutation of the KRAS
oncogene, which occurs in approximately 30 to 40% of
CRCs.4 The overall survival benefit in patients with stage
IV CRC following treatment with anti-EGFR therapies has
been modest; however, when patients are stratified for
KRAS mutation status, overall and progression-free sur-
vival rates are significantly improved for patients with
wild-type KRAS.5–10
The recent and consistent demonstrations of efficacy
for anti-EGFR therapies in KRAS wild-type CRC has re-
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sulted in a rapid increase in demand for mutation testing
in the clinical setting. Although a provisional clinical
opinion statement has recently been released by the
American Society of Clinical Oncology,7 no published
studies have evaluated the different testing methodol-
ogies that are currently available. The sensitivity and
specificity of each methodology is influenced by the
proportion of cancer cells in the sample, the quality of
DNA obtained, and inherent limitations of the technol-
ogy. CRCs are infiltrated by varying amounts of stromal
epithelium and normal cells such as fibroblasts and
lymphocytes, with the result that some clinical samples
may contain only a small proportion of mutated DNA.
The sensitivity of most assays for KRAS mutation de-
tection is therefore reliant on careful selection of tissue
samples that are enriched for tumor cells. This can be
further improved by microdissection or by core biopsy
sampling. Another major consideration for KRAS muta-
tion screening is the tissue source. The majority of
assays will necessarily be performed on archival for-
malin-fixed paraffin embedded (FFPE) samples from
the patient’s primary lesion, although biopsies from
metastatic cancer sites may be available in some
instances.
The vast majority of KRAS mutations occur in codon
12 or 13 of the gene, with a small minority of mutations
occurring in codon 61.11 A number of different KRAS
mutation detection methods are in routine laboratory
use, including automated dideoxy sequencing, pyro-
sequencing, single strand conformation polymorphism
(SSCP) analysis, and high resolution melting (HRM)
analysis. Sequence information is provided by the
former two methods, whereas a binary result is pro-
vided by the latter two. Although dideoxy sequencing
has long been considered the “gold standard” for mu-
tation detection, there is considerable evidence to sug-
gest that it may not be the most sensitive of these four
methods.12 The current study was designed to evalu-
ate four different KRAS mutation detection assays
(dideoxy sequencing, pyrosequencing, SSCP, and
HRM) currently in use across five clinical testing sites,
as well as two commercially available kits (TIB Molbiol
[Berlin, Germany] and DxS Diagnostic Innovations
[Manchester, UK]).
Materials and Methods
CRC Tissue Samples
CRC tissue samples were obtained from the CRC tissue
bank in the School of Surgery, University of Western
Australia. The first cohort was a consecutive series of 80
surgically resected, primary CRC specimens that were
snap frozen in liquid nitrogen and stored at70°C before
extraction of genomic DNA by using standard phenol
chloroform methods. The second cohort comprised 74
FFPE CRC samples. H&E-stained sections from this co-
hort were evaluated by a pathologist (K.T.) to estimate the
percentage of tumor cells. For FFPE samples, 2 to 3
sections (10-m thickness) were incubated for 10 min-
utes at 94°C in 300 l of digestion buffer (10 mmol/L
Tris-hydrochloric acid, pH 8.3; 1 mmol/L EDTA; 0.5%
Tween 20) followed by centrifugation at 13,000 rpm for 10
minutes.13 The surface paraffin layer was removed with a
tip and the tissue pellet was placed in a new tube con-
taining 200 l of digestion buffer. Proteinase K solution
was added (20 l of 20 mg/ml, Promega, Madison, WI)
and the samples were incubated for 72 hours at 55°C
with rotation. The enzyme was then inactivated by heat-
ing for 10 minutes at 94°C and the samples were centri-
fuged at 13,000 rpm for 10 minutes. The upper 100 l of
solution beneath the residual paraffin layer and contain-
ing the extracted DNA was removed and stored at 4°C for
PCR. All patients gave informed consent for the use of
stored tissues for molecular analysis.
Testing Sites and Methodologies Assessed
DNA from the two CRC cohorts was distributed to four
testing sites in Australia, two sites in Singapore, and one
site in the United Kingdom (Table 1). To limit variability
between testing sites, DNA was extracted from FFPE
samples at one site (Perth, Australia) before distribution.
Table 1. Mutation Detection Frequencies at Each Site
Testing site Method*
Frozen samples (n  80) FFPE samples (n  75)
No. mutations detected (%) % of consensus† No. mutations detected (%) % of consensus†
A SSCP 30/80 (37.5) 111.1 27/74 (36.5) 100.0
B Pyrosequencing 22/80 (27.5) 81.5 26/74 (35.1) 96.1
C HRM 128 bp 27/80 (33.8) 100.0 28/74 (37.8) 103.6
D HRM 80 bp 27/80 (33.8) 100.0 28/74 (37.8) 103.6
E Sequencing 28/80 (35.0) 104.5 23/70 (32.9) 90.1
F TIB Molbiol Kit 31/80 (38.8) 114.8 44/74 (59.5) 163.0
G DxS Kit 28/75 (37.3) 110.4 28/71 (39.4) 107.9
Consensus‡ 27/80 (33.8) 27/74 (36.5)
A, Perth, Australia; B, Newcastle, Australia; C, Melbourne, Australia; D, Brisbane, Australia; E, Department of Pathology, National University of
Singapore; F, Cancer Science Institute, National University of Singapore; G, Manchester, UK.
*Note that for the HRM 128 bp assay the target sequence is 92 bp, whilst the amplicon size is 128 bp due to the presence of M13 tags.
†The percentage of consensus value for each method is defined as the number of mutations detected by the method divided by the consensus
number of mutations (27 for both frozen and FFPE samples).
‡Consensus mutations were defined as those detected at five or more of the seven test sites.
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Additional sections of FFPE blocks were sent to each site
for re-extraction by individual testing centers as needed.
KRAS mutation assays were performed without knowl-
edge of the percentage of tumor cells estimated for each
sample.
SSCP Analysis
Fluorescent single SSCP analysis was performed in
Perth, Australia. Primers used for the KRAS assay (for-
ward, 5-GACTGAATATAAACTTGTGG-3; reverse, 5-
CTATTGTTGGATCATATTCG-3) were labeled at the 5
end with fluorescent HEX dye (GeneWorks, Adelaide,
Australia). PCR conditions were 5 minutes of denaturation
at 94°C during which time 1 l of DNA solution was
added, followed by 32 cycles of denaturation at 94°C,
annealing at 54°C, and extension at 72°C (40 seconds
each). The program was terminated by 7 minutes exten-
sion at 72°C. Three l of PCR product was mixed with 6
l of deionized formamide loading buffer containing
0.05% dextran blue and heated to 94°C for 5 minutes.
One microliter of this mixture was then loaded onto a
nondenaturing 10% polyacrylamide/2% glycerol gel
(100-m thickness, 18-cm length) and mounted in a DNA
fragment analyzer (GS-3000, Corbett Life Sciences, New
South Wales, Australia). Samples were pulse-loaded for
20 seconds at 1400V before rinsing the wells and then
running the gel for 1 hour at 1400V in 0.8 Tris-Borate-
EDTA buffer. Gel temperature was maintained at a con-
stant 24°C throughout the run by an inbuilt cooling unit.
The electrophoretogram was analyzed by using ONE-
Dscan 1.3 software (Scanalytics, Billerica, MA). DNA
samples that displayed bands additional to the wild-type
bands were classified as showing a mutation. Positive
controls comprising of DNA with known KRAS mutations
were run with each gel.
Pyrosequencing
The Pyrosequencing assay (Newcastle, Australia) was
performed according to the method of Ogino et al.12 A
5% threshold value was chosen arbitrarily to define the
presence of mutation.
HRM Analysis
HRM analysis was performed in Melbourne, Australia by
using a LightCycler 480 (Roche Diagnostics, Penzberg,
Germany) in a modification of the previously published
method of Krypuy et al.14 The reaction mixture contained
1 PCR buffer, 2.5 mmol/L MgCl2, 200 nmol/L of each
primer (5-TGTAAAACGACGGCCAGTTTATAAGGCCT-
GCTGAAAATGACTGAA-3 and 5-CAGGAAACAGCTA-
TGACCTGAATTAGCTGTATCGTCAAGGCACT-3, tagged
with M13 sequences [in bold] to allow direct sequencing
of the HRM product in the clinical setting), DNA template
of various concentrations, 200 mol/L dNTPs (Fisher Bio-
tec Australia, Wembley, Western Australia), 5 mol/L
SYTO 9 (Invitrogen, Carlsbad, CA), and 0.5U HotStarTaq
polymerase (Qiagen, Hilden, Germany) in a 10-l final
reaction volume. The cycling and melting conditions were
as follows: one cycle of 95°C for 10 minutes; 56 cycles of
95°C for 10 seconds; 60°C for 10 seconds with an initial
20 cycles of touchdown from 70°C (0.5°C/cycle); 72°C
for 20 seconds; one cycle of 97°C for 1 minute; and a
melt from 65°C to 95°C rising at 4.4°C/second. All sam-
ples were tested in triplicate. Mutations were visualized
using the LightCycler 480 software version 1.5 (Roche
Diagnostics).
HRM analysis was also performed (Brisbane, Australia)
on a Corbett Research RotorGene 6000 real-time PCR ma-
chine (Qiagen, Hilden, Germany). The reaction consisted
of 25 ng of DNA template, 1 PCR buffer, 2.5 mmol/L
MgCl2, 5 m of SYTO 9 (Invitrogen), 200 nmol/L each
of forward 5-TGAAAATGACTGAATATAAACTTGTGG-3
and reverse 5-CTGAATTAGCTGTATCGTCAAGG-3
primers, 0.5U of AmpliTaq Gold DNA Polymerase (Ap-
plied Biosystems, Foster City, CA), and water to a final
volume of 16 l. The polymerase was activated at 95°C
for 12 minutes before 40 amplification cycles of 95°C for
30 seconds, 60°C for 30 seconds, and 72°C for 30 sec-
onds. The product was denatured at 95°C for 5 minutes,
heteroduplexes were allowed to form at 50°C for 2 min-
utes and then the 80 base pair (bp) product was melted
over a gradient from 72 to 86°C rising by 0.2°C/second.
Mutations were visualized by using the normalized graph
and melt curve analysis software (Corbett Research).
Re-extraction of DNA as necessary from paraffin sections
was performed by using the QIAamp DNA FFPE tissue kit
(Qiagen) according to the manufacturer’s instructions.
Dideoxy Sequencing
Automated dideoxy sequencing was performed in the
Department of Pathology, National University of Singa-
pore, according to the methods of Krypuy et al.14 Follow-
ing PCR, products were purified with the ExoSap-IT re-
agent (USB, Cleveland, Ohio). Purified PCR product was
sequenced by using the BigDye Terminator version 3.1
Cycle Sequencing Kit (Applied Biosystems) and the
same primers were used for PCR. The 3100 Genetic
Analyzer (Applied Biosystems) was used for capillary
Figure 1. Frequency of KRAS mutation detection for frozen and FFPE
primary CRC samples among the different test sites. Samples were deemed
wild-type for KRAS when none of the centers or one center only detected a
mutation. The consensus for presence of KRAS mutation was when five or
more centers detected a mutation in that sample.
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Table 2. Mutation Detection in Frozen Tissue Samples
Sample no. SSCP Pyrosequencing HRM 92 bp HRM 80 bp Tib MolBiol Dideoxy sequencing DxS % Mutant
F1        0.0
F2        0.0
F3        0.0
F4        0.0
F5        0.0
F6        0.0
F7       ND 0.0
F8        0.0
F9        0.0
F10        0.0
F11        0.0
F12        0.0
F13        0.0
F14        0.0
F15        0.0
F16        0.0
F17        0.0
F18       ND 0.0
F19        0.0
F20        0.0
F21        0.0
F22        0.0
F23        0.0
F24        0.0
F25        0.0
F26        0.0
F27        0.0
F28        0.0
F29        0.0
F30        0.0
F31       ND 0.0
F32        0.0
F33        0.0
F34        0.0
F35        0.0
F36        0.0
F37        0.0
F38        0.0
F39        0.0
F40        0.0
F41        0.0
F42        0.0
F43        0.0
F44        0.0
F45     ●   14.3
F46     ●   14.3
F47       ● 14.3
F48     ●   14.3
F49       ● 14.3
F50     ●   14.3
F51 ●    ●   28.6
F52 ●      ● 28.6
F53 ●     ●  28.6
F54 ●  ● ●  ● ● 71.4
F55 ●  ● ● ● ● ● 85.7
F56 ●  ● ● ● ● ● 85.7
F57 ●  ● ● ● ● ● 85.7
F58 ●  ● ● ● ● ● 85.7
F59 ● ● ● ● ● ● ● 100.0
F60 ● ● ● ● ● ● ● 100.0
F61 ● ● ● ● ● ● ● 100.0
F62 ● ● ● ● ● ● ND 100.0
F63 ● ● ● ● ● ● ● 100.0
F64 ● ● ● ● ● ● ● 100.0
F65 ● ● ● ● ● ● ● 100.0
F66 ● ● ● ● ● ● ● 100.0
F67 ● ● ● ● ● ● ● 100.0
F68 ● ● ● ● ● ● ● 100.0
(table continues)
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electrophoresis and sequence analysis. All samples were
sequenced in both directions.
TIB Molbiol Kit
The TIB Molbiol KRAS mutation detection kit (LightMix Kit,
TIB Molbiol) was trialed at the Cancer Science Institute,
National University of Singapore and performed accord-
ing to the kit instructions. Briefly, 16 l of LightCycler
FastStart DNA Master Hyprobe (Roche Diagnostics) was
added to 113.8 l of TIB Molbiol reaction mixes and 15 l
of this solution was aliquoted into a capillary. Five micro-
liters (100 ng) of DNA was then added and PCR am-
plification and melting curve analyses were performed on
a LightCycler 2.0 (Roche Diagnostics).
DxS Kit
Mutation analysis for all samples was also performed by
using the DxS KRAS mutation detection kit by the manu-
facturers (DxS Diagnostic Innovations). This technology
combines allele specific PCR (ARMS) with real-time PCR
(Scorpions).
Statistical Analysis
Data from individual testing sites was sent to a central site
(Brisbane, Australia) for collation and analysis. Data were
analyzed by using GraphPad Prism 5 (GraphPad Soft-
ware, Inc, San Diego, CA). Direct estimates of sensitivity
and specificity were not possible as there was no reliable
predetermined gold standard method for comparison.
Results
The frequency of mutation detection across the different
testing centers is shown in Figure 1. A clear bimodal
distribution was observed for both frozen and FFPE sam-
ples. The raw data for frozen and FFPE samples is shown
in Tables 2 and 3, respectively. A “consensus mutation”
was called if a mutation was detected at five or more sites
(Table 1). Frequencies of the consensus mutations for
both frozen (27/80, 33.8%) and FFPE (27/74, 36.5%)
samples were consistent with reports in the literature. A
mutation was detected at just one or two testing sites in
9/80 (11.3%) frozen tissue samples compared with 21/74
(28.4%) FFPE samples. The poor concordance for FFPE
samples was largely due to the abnormally high mutation
frequency detected with the TIB Molbiol kit (44/74,
59.5%) compared with the consensus frequency of
36.5% (Table 3). For both frozen and FFPE samples,
100% concordance was observed between the two sites
that used HRM, despite the use of different primers,
reagents, assay conditions, and instruments.
Mutation Detection in Frozen Tissue Samples
In the series of frozen CRC tissues, full concordance (all
wild-type or all mutant) was observed for 66/80 (82.5%)
samples (Table 2). Mutations were detected in four sam-
ples (F55 to F58) by all methods except pyrosequencing,
and in one sample (F54) by all methods except pyrose-
quencing and the TIB Molbiol kit. KRAS mutations were
not detected in five samples (F54 to F58) by pyrose-
quencing, possibly reflecting low tumor cell content in
these samples. This was suggested by the low intensity
or magnitude of the aberrant bands observed for sample
F55 by using SSCP, HRM, and dideoxy sequencing (Fig-
ure 2, A–F). Mutations were detected in an additional nine
samples (F45 to F53) by two or fewer sites. Mutations
were detected in three samples by SSCP and one addi-
tional site. One of these was detected by SSCP and
sequencing (F53), and proved to be a bona fide muta-
tion, albeit outside of the codons 12 and 13 hotspots
(codon 20, ACG to ATG). One mutation was detected by
SSCP and DxS only and one by SSCP and the TIB Molbiol
kit only. Of the six mutations detected by a single site
only, four were by the TIB Molbiol kit alone and two were
by the DxS kit alone.
Mutation Detection in FFPE Tissue Samples
Concordance was seen across all testing sites in 46/74
(62.2%) FFPE samples. Compared with the overall muta-
tion frequency detected with other methodologies (range,
32.9 to 39.4%), a very high mutation frequency of 59.5%
Table 2. Continued
Sample no. SSCP Pyrosequencing HRM 92 bp HRM 80 bp Tib MolBiol Dideoxy sequencing DxS % Mutant
F69 ● ● ● ● ● ● ● 100.0
F70 ● ● ● ● ● ● ● 100.0
F71 ● ● ● ● ● ● ● 100.0
F72 ● ● ● ● ● ● ● 100.0
F73 ● ● ● ● ● ● ND 100.0
F74 ● ● ● ● ● ● ● 100.0
F75 ● ● ● ● ● ● ● 100.0
F76 ● ● ● ● ● ● ● 100.0
F77 ● ● ● ● ● ● ● 100.0
F78 ● ● ● ● ● ● ● 100.0
F79 ● ● ● ● ● ● ● 100.0
F80 ● ● ● ● ● ● ● 100.0
Closed circles indicate that a mutation was detected, whereas open circles indicate no mutation was detected. ND indicates no data were provided
by the testing site. Percent of samples with a KRAS mutation was calculated based on the number of sites where data were available.
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Table 3. Mutation Detection in FFPE Samples
Sample
no. % Tumor cells SSCP Pyrosequencing HRM 92 bp HRM 80 bp Tib MolBiol
Dideoxy
sequencing DxS % Mutant
P1 80        0.0
P2 30        0.0
P3 60       ND 0.0
P4 30        0.0
P5 50        0.0
P6 60       ND 0.0
P7 40        0.0
P8 15        0.0
P9 45        0.0
P10 70        0.0
P11 15        0.0
P12 50        0.0
P13 70        0.0
P14 30        0.0
P15 50        0.0
P16 80        0.0
P17 50        0.0
P18 30        0.0
P19 70        0.0
P20 40        0.0
P21 40        0.0
P22 60        0.0
P23 50        0.0
P24 80        0.0
P25 80        0.0
P26 20     ●   14.3
P27 40     ●   14.3
P28 10     ●   14.3
P29 30     ●   14.3
P30 30     ●   14.3
P31 50     ●   14.3
P32 50     ●   14.3
P33 40     ●   14.3
P34 80     ●   14.3
P35 20     ●   14.3
P36 30     ●   14.3
P37 60     ●   14.3
P38 30     ●   14.3
P39 40     ●   14.3
P40 50     ●   14.3
P41 70     ●   14.3
P42 60     ●   14.3
P43 70     ●   14.3
P44 80     ●   14.3
P45 20     ●  ND 16.7
P46 20     ● ND  16.7
P47 60   ● ●   ● 42.9
P48 40 ● ● ● ●  ND ● 83.3
P49 30 ● ● ● ●  ND ● 83.3
P50 50 ● ● ● ●  ND ● 83.3
P51 10 ●  ● ● ● ● ● 85.7
P52 30 ● ● ● ●  ● ● 85.7
P53 40 ● ● ● ● ●  ● 85.7
P54 80 ● ● ● ● ● ● ● 100.0
P55 60 ● ● ● ● ● ● ● 100.0
P56 30 ● ● ● ● ● ● ● 100.0
P57 30 ● ● ● ● ● ● ● 100.0
P58 30 ● ● ● ● ● ● ● 100.0
P59 60 ● ● ● ● ● ● ● 100.0
P60 70 ● ● ● ● ● ● ● 100.0
P61 80 ● ● ● ● ● ● ● 100.0
P62 20 ● ● ● ● ● ● ● 100.0
P63 25 ● ● ● ● ● ● ● 100.0
P64 40 ● ● ● ● ● ● ● 100.0
P65 50 ● ● ● ● ● ● ● 100.0
P66 30 ● ● ● ● ● ● ● 100.0
P67 30 ● ● ● ● ● ● ● 100.0
(table continues)
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was seen by using the TIB Molbiol kit. If data from this
assay were excluded from the paraffin series, an excel-
lent concordance between sites was observed (100%
concordance in 71/74 samples). Excluding data from the
TIB Molbiol kit, discordance was seen in only three sam-
ples. A mutation in sample P47 was not detected by
SSCP, pyrosequencing, or dideoxy sequencing (60% tu-
mor cell content), in P53 by dideoxy sequencing alone
(40% tumor cell content) or in P51 by pyrosequencing
alone (10% tumor cell content). No result was reported in
four samples by dideoxy sequencing (P46, P48, P49, and
P50) and three samples by DxS (P3, P6, and P45) be-
cause they did not meet the quality assurance conditions
imposed by these testing sites.
Detection of Different Types of KRAS Mutations
An advantage of automated dideoxy sequencing, pyro-
sequencing, and the TIB Molbiol and DxS mutation de-
tection kits is that the type of KRAS mutation is deter-
mined. We therefore compared the specificity of
detection of each mutation type across these four meth-
odologies in both the frozen and FFPE series (Table 4).
Excellent concordance was seen for all but the TIB Mol-
biol kit where the incorrect mutation type was reported in
7/26 (26.9%) frozen samples and 2/22 (9.1%) FFPE sam-
ples. Consensus for mutation type was not reached in
one other FFPE sample (P73), with dideoxy sequencing
and DxS reporting a 12V mutation, whereas pyrose-
quencing and the TIB Molbiol kit reported a 12A mutation.
Discussion
This study evaluated various KRAS mutation screening
techniques in two series of primary CRC tissues totaling
154 samples. The first series comprised high quality DNA
extracted from unfixed, frozen tumor specimens, while
the second series comprised archival FFPE samples. The
latter are more representative of the source material used
in KRAS testing centers. DNA was extracted centrally and
distributed to seven sites that independently screened for
KRAS mutations by using different methodologies, in-
cluding two commercially available mutation detection
kits. This is the first study to assess the concordance of
different methods for the detection of KRAS mutation
across multiple testing sites and using clinical speci-
mens. Although excellent agreement between methods
was observed, it was less than 100%. This raises issues
about what the gold standard for KRAS mutation detec-
tion should be for routine clinical testing.
DNA quality is a potentially important factor affecting
the performance of KRAS mutation assays. In the clinical
setting the tissue source will usually be archival FFPE
blocks from surgically resected primary cancers, al-
though there are also a significant proportion of biopsy
samples from the primary or metastatic lesion. Formalin
fixation dramatically reduces DNA quality; however, this
did not appear to have a negative impact on assay per-
formance in this study, as judged by the high degree of
concordance between different techniques. The excep-
tion to this was the TIB Molbiol kit. Although this kit
performed reasonably well with frozen tissue DNA, it
gave an unacceptably high frequency of false positive
results with FFPE samples. The DNA extraction proce-
dure used here for FFPE tissues was a simple Proteinase
K-based digestion method. It worked particularly well for
the SSCP and pyrosequencing assays; however, other
purification methods may have increased the data con-
Table 3. Continued
Sample
no. % Tumor cells SSCP Pyrosequencing HRM 92 bp HRM 80 bp Tib MolBiol
Dideoxy
sequencing DxS % Mutant
P68 60 ● ● ● ● ● ● ● 100.0
P69 50 ● ● ● ● ● ● ● 100.0
P70 30 ● ● ● ● ● ● ● 100.0
P71 20 ● ● ● ● ● ● ● 100.0
P72 30 ● ● ● ● ● ● ● 100.0
P73 60 ● ● ● ● ● ● ● 100.0
P74 40 ● ● ● ● ● ● ● 100.0
Closed circles indicate that a mutation was detected, whereas open circles indicate no mutation was detected. ND indicates no data were provided
by the testing site. Percent of samples with a KRAS mutation was calculated based on the number of sites where data were available.
Figure 2. Mutation detection by using SSCP, HRM, and dideoxy sequencing.
Raw data were shown for frozen sample 55 (F55). Where a faint band was
detected by SSCP (A; , negative control; , positive control), a clear
difference in melt temperature was detected by HRM 82 bp assay (B, mutant
indicated by arrows) and subtle variant peak identified by dideoxy sequenc-
ing (C). Similarly, a mutation in FFPE sample 51 (P51) estimated to have a
10% tumor cell content is shown by using SSCP (D), HRM 82 bp assay
(E, mutant indicated by arrows), and dideoxy sequencing (F).
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cordance for some of the other methods, especially the
TIB Molbiol kit. No result could be obtained for five
frozen tissue and three FFPE tissue samples by the
DxS method and for four FFPE series samples by
dideoxy sequencing.
The use of a small amplicon or target DNA fragment
size is important for assay success when using FFPE
samples. Assay design is critical for methods such as
dideoxy sequencing where the amplicon should be of
sufficient size to allow high quality sequence information
across the region of interest, and that region should be
centrally placed in the amplicon to allow high quality
forward and reverse sequence.
Another key determinant of assay performance is the
relative tumor cell content of tissue samples. Four of the
FFPE samples in this study were estimated to have a
tumor cell content of less than 20% (P8, P11, P28, and
P51). One of these (P51, estimated 10% tumor cells) was
found to contain a mutation by using all methods except
pyrosequencing. On the other hand, three FFPE samples
with 20 to 25% tumor cell content (P62, P63, and P71)
were found to contain a mutation at all seven test sites,
indicating that a 20% threshold for minimum tumor cell
content is appropriate. Significant enrichment for tumor
cells can be achieved by routine microdisection or core
biopsy of FFPE blocks following identification of suitable
areas by a histopathologist. Case review by a his-
topathologist is essential in solid tumor testing and further
involvement in block selection and tumor cell enrichment
by a histopathologist with an understanding of the asso-
ciated molecular test will enhance this process.15 It
should be noted that, in the clinical setting, tissue micro-
dissection is routinely conducted by the Melbourne
(HRM) and Singapore (dideoxy sequencing) sites and
core sampling is performed by the Newcastle site (pyro-
sequencing), thus minimizing the impact of a low tumor to
normal cell ratio. In addition to samples with a high de-
gree of stromal involvement, histological evaluation will
be particularly important for cancers treated with chemo-
radiation where few tumor cells may remain. In this in-
stance it may be necessary to access the original diag-
nostic biopsy rather than surgical resection specimen.
A further consideration regarding tissue source is
whether the sample is obtained from the primary cancer
or a metastatic site. It could be argued that therapy
should be directed against the metastatic disease. How-
ever, in the large majority of cases only the primary tumor
specimen will be available for analysis. KRAS is believed
Table 5. Estimates of Assay Cost and Turnover Time
Method
Reagent
costs
Labor
time
Turnover
time, hours*
SSCP   5
HRM   2.5
Pyrosequencing   3.5
Sequencing   5
TIB Molbiol   2.5
DxS   2.5
*Exclusive of DNA extraction.
Table 4. Types of Mutations Detected
Frozen Tissue Paraffin Tissue
Sample
no.
Dideoxy
sequencing Pyrosequencing DxS TIB-Molbiol
Sample
no.
Dideoxy
sequencing Pyrosequencing DxS TIB-Molbiol
F65 12A 12A 12A 12D P60 12A 12A 12A 12D
F55 12C wt 12C 12C P54 12A 12A 12A 12D
F77 12C 12C 12C 12C P49 ND 12A 12A wt
F79 12C 12C 12C 12C P73 12V 12A 12V 12A
F54 12C wt 12C wt P59 12C 12C 12C 12C
F66 12D 12D 12D 12D P68 12C 12C 12C 12C
F69 12D 12D 12D 12D P52 12C 12C 12C wt
F74 12D 12D 12D 12D P48 ND 12C 12C wt
F76 12D 12D 12D 12D P61 12D 12D 12D 12D
F62 12D 12D ND 12D P63 12D 12D 12D 12D
F60 12D 12D 12D 12D P70 12D 12D 12D 12D
F61 12D 12D 12D 12D P72 12D 12D 12D 12D
F56 12D wt 12D 12D P57 12S 12S 12S 12S
F58 12D wt 12D 12D P64 12S 12S 12S 12S
F78 12S 12S 12S 12S P55 12V 12V 12V 12V
F63 12V 12V 12V 12A P58 12V 12V 12V 12V
F64 12V 12V 12V 12A P67 12V 12V 12V 12V
F71 12V 12V 12V 12A P56 12V 12V 12V 12V
F72 12V 12V 12V 12A P53 wt 12V 12V 12V
F59 12V 12V 12V 12V P69 12V 12V 12V 12V
F67 12V 12V 12V 12V P50 ND 12V 12V wt
F75 12V 12V 12V 12V P62 13D 13D 13D 13D
F73 12V 12V ND 12V P65 13D 13D 13D 13D
F57 12V wt 12V 12A P66 13D 13D 13D 13D
F68 13D 13D 13D 13D P71 13D 13D 13D 13D
F70 13D 13D 13D 13D P74 13D 13D 13D 13D
F80 12A 12A 12A 12D P51 12D wt 12D 12D
wt, wild-type; ND, no data; discordant data shown in bold.
Data are shown only if a mutation was detected at two or more sites.
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to be mutated early in the adenoma-carcinoma progres-
sion and hence the metastatic tissues should be clonally
derived from the primary tumor. This is supported by a
recent study showing a high level of concordance for
KRAS mutation status in 95/99 (96.0%) matched primary
and metastatic CRC samples.16
The utility of sequence information should also be con-
sidered when choosing the assay. Although uncommon,
mutations do exist outside the major codon 12/13 hot-
spots.17,18 These may not activate MAPK signaling and
this should be considered before denial of therapy. A
single example of such a mutation (codon 20, ACG to
ATG) was detected by SSCP and dideoxy sequencing
(F53). A database of sequence variants may be useful for
future determination of the clinical relevance of uncom-
mon mutations. Such a database should include reports
of uncommon mutations, details of clinical management
and patient outcome as well as any available evidence
for impact on MAPK pathway signaling.
Cost and turnaround time of assays are also important
factors for routine clinical testing (Table 5). SSCP, HRM,
and pyrosequencing are rapid, high-throughput and in-
expensive methods that performed well in this study for
both frozen and FFPE samples. The dideoxy sequencing
assay was more expensive than each of these methods.
However, one advantage of this method is that DNA
sequencing services are widely available in many cen-
ters. In addition, sequencing is a necessary quality con-
trol step for the SSCP and HRM assays.
The DxS kit performed well in this study and offers a
rapid, standardized and high-throughput platform. How-
ever, the cost of this assay means that it could be pro-
hibitive for many clinical testing facilities. In addition,
patients with rarer codon 13 mutations will not be de-
tected. The poor performance of the TIB Molbiol kit for
FFPE samples indicates that it may not be suitable for use
in the clinical setting.
A further important consideration in the method of
choice for KRAS mutation screening is the equipment
and technical expertise that are available at each testing
site. These tests must be performed in conjunction with
an anatomical pathologist to review the tumor cell content
of samples and with an experienced molecular geneticist
to review the mutation results.
Other molecular events may account for the resistance
to anti-EGFR therapies seen in some patients with wild-
type KRAS. There is clinical evidence that the V600E
hotspot mutation in the BRAF oncogene also confers
resistance to cetuximab.19 BRAF functions downstream
of KRAS in the MAPK pathway and mutations of BRAF
and KRAS are mutually exclusive. Clinical testing for
BRAF mutation will therefore also play an important role in
predicting response to anti-EGFR therapies and will need
to be implemented with consideration of the same issues
discussed here for KRAS testing. Other evidence is ac-
cumulating for a possible role of disrupted PIK3CA,
PTEN, amphiregulin, and epiregulin in determining the
response to anti-EGFR therapies.20–24
This study has demonstrated a high degree of concor-
dance in KRAS mutation detection for routine testing
methodologies across different testing sites. Discordant
results for pyrosequencing in the frozen tumor series may
have been due to lower tumor cell content in these sam-
ples. Based on the results of our study, the SSCP, HRM,
dideoxy sequencing, and pyrosequencing methods ap-
pear to be suitable and cost-effective assays for KRAS
testing of clinical specimens. It is important, however,
that suitably qualified personnel are used to establish
these techniques and to perform ongoing quality control
testing. The sensitivity of some methods may be in-
creased by prior tumor cell enrichment by using micro-
dissection or core biopsy, and by the use of column-
based DNA extraction procedures. Because metastatic
CRC has a high frequency of KRAS mutation and the time
required to obtain a result is often dependent on the
speed of retrieval of archival FFPE blocks, routine KRAS
mutation testing at the time of surgical resection may also
be worth considering.
The discovery that response to anti-EGFR therapy is
modulated by the mutation status of the KRAS oncogene
represents a major advance in clinical oncology and is an
exciting step toward personalized medicine for ad-
vanced CRC. This has prompted the rapid introduction of
molecular testing in molecular pathology laboratories
worldwide. The data presented here indicate that a vari-
ety of techniques are suitable for KRAS mutation analysis
in the clinical setting. As further molecular targets are
shown to have a role in predicting response to anti-EGFR
and other targeted therapies, there will be a rapid in-
crease in the need for mutation testing in the clinical
setting. The choice of method used by different labora-
tories is likely to depend on the equipment and technical
expertise available, as well as the importance of cost and
throughput of each method to those laboratories.
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